Center for Vaccine Innovation and Access, PATH, Seattle, Washington, USA.
Clinical Research Programme, Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
J Pediatric Infect Dis Soc. 2020 Dec 31;9(6):738-745. doi: 10.1093/jpids/piaa157.
Respiratory syncytial virus (RSV) is a leading cause of respiratory illness among infants globally, yet economic burden data are scant, especially in low-income countries.
We collected data from 426 infants enrolled in the Queen Elizabeth Central Hospital respiratory disease surveillance platform to estimate the household and health system costs of managing RSV and other respiratory pathogens in Malawian infants. Total household cost per illness episode, including direct and indirect costs and lost income, was reported by parents/guardians at the initial visit and 6 weeks post discharge. The total cost to the health system was based on patient charts and hospital expenditures. All-cause acute respiratory infections (ARIs) and RSV costs for inpatient and outpatients are presented separately. All costs are in the 2018 US Dollar.
The mean costs per RSV episode were $62.26 (95% confidence interval [CI]: $50.87-$73.66) and $12.51 (95% CI: $8.24-$16.79) for inpatient and outpatient cases, respectively. The mean cost per episode for all-cause ARIs was slightly higher among inpatients at $69.93 (95% CI: $63.06-$76.81) but slightly lower for outpatients at $10.17 (95% CI: $8.78-$11.57). Household costs accounted for roughly 20% of the total cost per episode. For the lowest-income families, household cost per inpatient RSV episode was about 32% of total monthly household income.
Among infants receiving care at a referral hospital in Malawi, the cost per episode in which RSV was detected is comparable to that of other episodes of respiratory illnesses where RSV was not detected. Estimates generated in this study can be used to evaluate the economic and financial impact of RSV and acute respiratory illness preventive interventions in Malawi.
呼吸道合胞病毒(RSV)是全球婴儿呼吸道疾病的主要病因,但经济负担数据很少,特别是在低收入国家。
我们从在伊丽莎白女王中央医院呼吸道疾病监测平台登记的 426 名婴儿中收集数据,以估计马拉维婴儿管理 RSV 和其他呼吸道病原体的家庭和卫生系统成本。父母/监护人在初次就诊和出院后 6 周时报告每个疾病发作的总家庭成本,包括直接和间接成本以及收入损失。根据患者病历和医院支出计算卫生系统总成本。分别报告门诊和住院患者的所有病因急性呼吸道感染(ARI)和 RSV 成本。所有成本均以 2018 年美元计。
RSV 住院和门诊病例的平均每个病例成本分别为 62.26 美元(95%置信区间[CI]:50.87-73.66)和 12.51 美元(95%CI:8.24-16.79)。住院患者所有病因 ARI 的平均每个病例成本略高,为 69.93 美元(95%CI:63.06-76.81),但门诊患者略低,为 10.17 美元(95%CI:8.78-11.57)。家庭成本占每个病例总成本的 20%左右。对于收入最低的家庭,住院 RSV 病例的家庭成本约占家庭月总收入的 32%。
在马拉维一家转诊医院接受治疗的婴儿中,RSV 检出病例的每个病例成本与未检出 RSV 的其他呼吸道疾病病例的成本相当。本研究中生成的估计数可用于评估 RSV 和急性呼吸道疾病预防干预措施对马拉维的经济和财务影响。